Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Double-blind, Placebo-controlled, Randomized, Single and Multiple Ascending Dose Finding Study to Evaluate the Safety and Pharmacokinetic Profile of LSALT Peptide in Healthy Participants

Trial Profile

A Phase I Double-blind, Placebo-controlled, Randomized, Single and Multiple Ascending Dose Finding Study to Evaluate the Safety and Pharmacokinetic Profile of LSALT Peptide in Healthy Participants

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Dec 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Metablok (Primary)
  • Indications Acute kidney injury; Cancer metastases; Sepsis
  • Focus Adverse reactions
  • Sponsors Arch Biopartners
  • Most Recent Events

    • 04 Dec 2019 According to an Arch Biopartners media release, an update on the trial will be provided by Arch following the dosing of the 44th volunteer, which is expected shortly.
    • 07 Nov 2019 Results published in Arch Biopartners Inc Media Release
    • 07 Nov 2019 According to an Arch Biopartners media release, testing Metablok in 3-day, multiple ascending dose cohorts of eight volunteers per cohort has already begun. This second part of the study, representing the expected dosing schedule for the Phase II trial, is expected to be completed by the end of November
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top